NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $16.07 +0.06 (+0.37%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$15.84 -0.23 (-1.40%) As of 11/13/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sarepta Therapeutics Stock (NASDAQ:SRPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$15.70▼$16.2350-Day Range$16.01▼$22.5052-Week Range$14.68▼$24.68Volume1.32 million shsAverage Volume2.31 million shsMarket Capitalization$1.72 billionP/E RatioN/ADividend YieldN/APrice Target$23.67Consensus RatingHold Company Overview Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD. Sarepta is headquartered in Cambridge, Massachusetts. In addition to developing and commercializing treatments, the company conducts research into genetic medicines for other rare diseases.AI Generated. May Contain Errors. Read More Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreSRPT MarketRank™: 3.751148444675 of 5 starsSarepta Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 106th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingSarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and 6 sell ratings.Upside PotentialSarepta Therapeutics has a consensus price target of $23.67, representing about 47.3% upside from its current price of $16.07.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-59.02% Earnings GrowthEarnings for Sarepta Therapeutics are expected to decrease by -59.02% in the coming year, from $3.27 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSarepta Therapeutics has a PEG Ratio of 0.38. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.33% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 7.82.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 13.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.58 News SentimentSarepta Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Sarepta Therapeutics this week, compared to 7 articles on an average week.Search Interest8 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Stock News HeadlinesSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Deutsche BankNovember 12 at 2:13 AM | americanbankingnews.comSarepta Therapeutics, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 10, 2026 | seekingalpha.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 15 at 1:00 AM | Profits Run (Ad)Sarepta Updates High-Dose Eteplirsen Study in Duchenne Muscular DystrophyNovember 10, 2026 | tipranks.comDeutsche Bank Upgrades Sarepta Therapeutics to Hold From Sell, Raises Price Target to $18 From $14November 10, 2026 | marketscreener.comMSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00November 9, 2026 | americanbankingnews.comSarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call TranscriptNovember 7, 2026 | seekingalpha.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Consensus Target Price of $23.40 According to AnalystsNovember 7, 2026 | americanbankingnews.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $21.52 on January 1st, 2026. Since then, SRPT shares have decreased by 25.3% and is now trading at $16.07. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Thursday, November, 5th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. The firm's revenue for the quarter was down 4.5% compared to the same quarter last year. Read the conference call transcript. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiaries of Sarepta Therapeutics: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional shareholders include State Street Corp (6.91%), First Trust Advisors LP (4.59%), Marshall Wace LLP (1.88%) and Pictet Asset Management Holding SA (0.65%). Insiders that own company stock include Michael Andrew Chambers, Ian Michael Estepan, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include NVIDIA (NVDA), Tesla (tsla), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Netflix (NFLX) and Gilead Sciences (GILD). Company Calendar Last Earnings11/05/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 10 days, SRPT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sarepta.com Phone(617) 274-4000Fax425-354-5038Employees835Year Founded1980Price Target and Rating Average Price Target for Sarepta Therapeutics$23.67 High Price Target$38.00 Low Price Target$5.00 Potential Upside/Downside+47.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E Ratio11.99 P/E Growth0.38Net Income-$713.41 million Net Margins-5.86% Pretax Margin-4.70% Return on Equity-0.20% Return on Assets-0.09% Debt Debt-to-Equity Ratio0.46 Current Ratio3.46 Quick Ratio2.13 Sales & Book Value Annual Sales$2.20 billion Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$14.26 per share Price / Book1.13Miscellaneous Outstanding Shares107,240,000Free Float99,837,000Market Cap$1.72 billion OptionableOptionable Beta0.45 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SRPT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.